Treatment of<unk>  has not been well investigated. Initial drug studies were done only with the ADHD medication methylphenidate (e.g. Ritalin®), and even then only with children who were diagnosed as ADD without hyperactivity (using DSM-III criteria) and not specifically for<unk> . The research seems to have found that most children with ADD (attention deficit disorder) with Hyperactivity (currently ADHD combined type) responded well at medium-to-high doses. However, a sizable percentage of children with ADD without hyperactivity (currently ADHD inattentive type, therefore the results may apply to<unk>  did not gain much benefit from methylphenidate, and when they did benefit, it was at a much lower dose. Risperidone is a recent offlabel treatment that has been proven to be successful in clinical trials eliminating the trouble in only a few weeks of treatment, when the incidence its low and the type of<unk>  its<unk> ral and not persistent, in that cases it eliminates the need of any other medication. Risperidone is effective also as ADHD treatment. The use of low dose risperidone and other antipsychotic drugs off-label as augmentation treatment for adolescents with Attention Deficit Hyperactivity Disorder (ADHD) and Disruptive Behavioral Disorder (DBD) has become widely common worldwide, usually to help control behavioral difficulties. While some argue that agents that block dopaminergic receptors may have a deleterious<unk>  effect, others stress their moderating effects, which possibly improve function in all domains, including<unk>  functions. Modafinil its been used with medium success in a few cases of<unk> , in both:<unk> ral and persistant cases. However, one study and a retrospective analysis of medical histories found that the presence or absence of<unk>  symptoms made no difference in response to methylphenidate in children with ADHD-I. But these studies did not specifically and explicitly examine the effect of the drug on<unk>  symptoms in children. The medication studies who did this found atomoxetine (Strattera) to have significant beneficial effects that were independent of ADHD symptoms and a poor response for methylphenidate. Only one study has investigated the use of behavior modification methods at home and school for children with predominantly<unk>  symptoms and it found good success. In April 2014, The New York Times reported that<unk>  is the subject of pharmaceutical company clinical drug trials, including ones by Eli Lilly that proposed that one of its biggest-selling drugs, Strattera, could be prescribed to treat proposed symptoms of<unk> . Other researchers believe that there is no effective treatment for<unk> .
Sluggish cognitive tempo
Compulsive behavior
Social-emotional agnosia
Psychological resistance
Callous and unemotional traits
Musical anhedonia
Emotional lability
Communication apprehension